Canine IBD Hero Mb 2x

The Canine
CE-IBD Assay

Diagnose and monitor patients with chronic enteropathy with a simple, affordable blood test

Vomiting, diarrhea, and other gastrointestinal signs are among the most common reasons for a dog to require a visit to the veterinarian. Ascertaining the cause of these signs is often a time-consuming task for clinicians and a frustrating and expensive process for pet owners, especially in the case of a complex condition like chronic enteropathy (commonly referred to as inflammatory bowel disease).

Canine IBD Feature 05 Dskt flip
Canine IBD Feature 04 Dskt

The CE-IBD Assay uses three intestinal biomarkers in an innovative approach for diagnosing and monitoring chronic enteropathy

The CE-IBD Assay uses three individual biomarkers in combination to provide a result of consistent or not consistent with chronic enteropathy. Trending the results of the individual biomarkers can be useful in monitoring response to therapy.

ANTI-PORIN IGA:

  • Marker indicating increased intestinal permeability resulting in antibody production to an outer membrane protein of Escherichia coli
  • Short for: anti-outer-membrane porin C (OmpC) IgA antibodies / Abbreviation: ACA
  • Interpretive Ranges:
    • Low <15 EU/mL
    • Intermediate 15–40 EU/mL
    • High >40 EU/mL

ANTI-CALPROTECTIN IGA:

  • Marker indicating intestinal inflammation
  • Short for: anti-canine calprotectin IgA antibodies / Abbreviation: ACNA
  • Interpretive Ranges:
    • Low <6 EU/mL
    • Intermediate 6–15 EU/mL
    • High >15 EU/mL

ANTI-GLIADIN IGA:

  • Marker indicating possible food sensitization in particular to gliadins (a component of gluten)
  • Short for: Anti-gliadin IgA antibodies / Abbreviation: AGA
  • Interpretive Ranges:
    • Low <50 EU/mL
    • Intermediate 50–60 EU/mL
    • High >60 EU/mL
Canine IBD feature 03 Dskt

Using The Canine CE-IBD Assay

The CE-IBD Assay has value when patients are on a therapeutic dietary trial, antibiotics, corticosteroids, and other immunosuppressive agents.

Diagnosis

If you are using this assay to help in diagnosing chronic enteropathy, the dog should be off any therapeutic diet and all medications that may impact the gastrointestinal tract for at least 7 days. However, if the dog is responding well, do not stop therapeutic dietary trial or medications; instead, use the assay as a monitoring test.

Retesting

2 to 4 weeks after initiation of therapeutic dietary trial and/or medications and after changes in diet or medications. Every 2 to 3 months once patient is stable; the testing interval can be increased over time.

Monitoring

Monitoring response to treatment is an excellent use of this assay; dogs should remain on therapeutic diet and all treatments. Use clinical signs and trends in the assay’s biomarker concentrations to assess response to management.
CE IBD Assay Algorithm 01

Antech Canine GI Diagnostic Algorithm

Diagnostic and therapeutic approach to a dog with chronic gastrointestinal signs.

Download Canine GI Diagnostic Algorithm

Canine IBD Feature 02 Mb 2x

Increase confidence and compliance

The CE-IBD Assay helps raise the veterinary team's confidence when diagnosing and treating chronic patients and helps drive increased compliance by pet owners – leading to getting sick pets healthier faster.

For veterinarians

  • Increases confidence to recommend additional diagnostics in sicker dogs when results are consistent with chronic enteropathy to further evaluate the cause of GI signs
  • Allows veterinarians to recommend a dietary trial in stable patients when results are consistent with CE/IBD, and, in some cases, provide guidance on which diet to select
  • Provides evidence in dogs where test results are not consistent with chronic enteropathy, therefore additional diagnostics are needed to determine the dog’s underlying disease

For pet parents

  • Increases compliance when additional diagnostics are recommended
  • Improves diligent compliance with dietary trial recommendations

Sign up to learn more about the Canine CE-IBD Assay

RenalTech™

Take the surprise out of chronic kidney disease with artificial intelligence

Available exclusively through Antech, RenalTech™ is a breakthrough in predictive medicine. Powered by artificial intelligence, RenalTech™ uses common serum and urine diagnostics to predict whether a cat will develop chronic kidney disease in the next two years—with greater than 95% accuracy.

Learn More
Canine CE-IBD Assay

Learn how the CE-IBD Assay can guide you to diagnosis and treatment success

Rapid access to effective treatment for CE/IBD is the goal. It’s also essential as the disease can have a serious impact on a dog’s health and overall well-being. An affected dog generally experiences vomiting and/or diarrhea, poor appetite, weight loss, flatulence and abdominal discomfort for approximately at least 3 weeks before CE/IBD can be ruled in with certainty, though many practitioners may begin to suspect the condition earlier based on clinical experience.

Renal Tech Anouncement

Innovations
Close
RenalTech
inspires more veterinary visits and better preventive care for cats
Learn More